Saturday, 30 June 2012

'Smoking vaccine' blocks nicotine in mice brains


Man smoking Researchers believe vaccines may one day help people if they choose to quit.

Related Stories

Smokers could one day be immunised against nicotine so they gain no pleasure from the habit, according to researchers in the US.
They have devised a vaccine that floods the body with an antibody to assault nicotine entering the body.
A study in mice, published in Science Translational Medicine, showed levels of the chemical in the brain were reduced by 85% after vaccination.
Years of research are still needed before it could be tested on people.
However, lead researcher Prof Ronald Crystal is convinced there will be benefits.
"As far as we can see, the best way to treat chronic nicotine addiction from smoking is to have these Pacman-like antibodies on patrol, clearing the blood as needed before nicotine can have any biological effect."
New approach Other "smoking vaccines" have been developed that train the immune system to produce antibodies that bind to nicotine - it is the same method used to vaccinate against diseases. The challenge has been to produce enough antibodies to stop the drug entering the brain and delivering its pleasurable hit.
Scientists at Weill Cornell Medical College have used a completely different approach, a gene-therapy vaccine, which they say is more promising.

Start Quote

If they start smoking again, they will receive no pleasure from it due to the nicotine vaccine, and that can help them kick the habit”
End Quote Prof Ronald Crystal Weill Cornell Medical College
A genetically modified virus containing the instructions for making nicotine antibodies is used to infect the liver. This turns the organ into a factory producing the antibodies.
The research team compared the amount of nicotine in the brains of normal mice with those that had been immunised. After being injected with nicotine, the vaccinated mice had nicotine levels 85% lower.
It is not known if this could be repeated in humans or if this level of reduction would be enough to help people quit.
Prof Crystal said that if such a vaccine could be developed then people "will know if they start smoking again, they will receive no pleasure from it due to the nicotine vaccine, and that can help them kick the habit".
He added: "We are very hopeful that this kind of vaccine strategy can finally help the millions of smokers who have tried to stop, exhausting all the methods on the market today, but find their nicotine addiction to be strong enough to overcome these current approaches."
'Impressive and intriguing' There are also issues around the safety of gene therapy in humans that will need to be answered.
Professor of genetics at the University of Kent, Darren Griffin, said the findings were "impressive and intriguing with great potential" but cautioned there were still many issues which needed addressing.
He said the main issue "is whether the observed biochemical effects in lab mice genuinely translate to a reduced addiction in humans given that such addictions can be both physical and psychological".
Dr Simon Waddington, from University College London, said: "The technology underpinning gene therapy is improving all the time and it is encouraging to see these preliminary results that indicate it could be used to address nicotine addiction, which is damaging to the nation's health and a drain on the health service economy."
If such a vaccine was developed it could also raise ethical questions about vaccinating people, possibly in childhood, before they even started smoking.

HIV quad pill 'may improve care'


HIV The 'quad' is the first multi-pill to include a type of anti-HIV drug known as an integrase inhibitor

Related Stories

A new once-a-day pill which combines four HIV drugs into a single daily treatment is safe and effective, according to a US study.
It is hoped the four-in-one "quad pill" will make it easier for patients to stick to their medication, improving the effects of their treatment.
A study in the Lancet said it could be an "important new treatment option".
A UK expert said the pill was "great news" and was part of a movement towards once-daily doses.
HIV is incurable, but managing the infection requires combination therapy - multiple drugs used to control the virus.
This can mean taking several pills at different times of the day - and missing them means the body can lose the fight against the virus.
Researchers and drug companies have combined some drugs into single pills so that taking the correct medication at the right time of day is easier.
The quad pill is the first to include a type of anti-HIV drug known as an integrase inhibitor, which stops the virus replicating.

Start Quote

Without a doubt the achievement of a one-a-day pill has been a big advance in tackling HIV”
End Quote Dr Steve Taylor Birmingham Heartland Hospital
'Safe, simple, effective'
Paul Sax, clinical director at Brigham and Women's Hospital, in Boston, Massachusetts, and associate professor at Harvard Medical School, said: "Patient adherence to medication is vital, especially for patients with HIV, where missed doses can quickly lead to the virus becoming resistant to medication."
He led research comparing the effect of the quad pill with the current best treatment in 700 patients. He said the quad pill was as safe and effective, although there was a higher level of kidney problems among those taking it.
"Our results provide an additional highly potent, well-tolerated treatment option and highlight the simplicity of treatment resulting from combining several antiretrovirals in a single pill.
Dr Steve Taylor, an HIV specialist at Birmingham Heartland Hospital, said: "Without a doubt the achievement of a one-a-day pill has been a big advance in tackling HIV.
"We've come a long way from people taking up to 40 pills three times a day."
He said the new tablet was "great news" for people with HIV and would increase options for treatment.
However, he warned that too many people still had undiagnosed HIV. A quarter of people with HIV in the UK do not know they are infected.
The researcher was funded by the biotechnology company Gilead Sciences.

More on This Story

Related Stories